Infliximab versus interferon-alpha in the treatment of Behçet’s Syndrome: Clinical data from the BIO-BEHÇET’S randomised controlled trial

Moots, R.J., Fortune, F., Jackson, R. et al. (6 more authors) (2024) Infliximab versus interferon-alpha in the treatment of Behçet’s Syndrome: Clinical data from the BIO-BEHÇET’S randomised controlled trial. Rheumatology. keae585. ISSN 1462-0324

Abstract

Metadata

Item Type: Article
Authors/Creators:
Keywords: Behçet’s, randomised controlled clinical trial, infliximab, interferon, biologic therapy
Dates:
  • Published (online): 21 October 2024
  • Accepted: 22 August 2024
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM) > Discovery & Translational Science Dept (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 20 Feb 2025 15:39
Last Modified: 20 Feb 2025 15:39
Status: Published online
Publisher: Oxford University Press (OUP)
Identification Number: 10.1093/rheumatology/keae585
Related URLs:
Sustainable Development Goals:
  • Sustainable Development Goals: Goal 3: Good Health and Well-Being
Open Archives Initiative ID (OAI ID):

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics